Objective-Deep venous thrombosis is a major health problem. Thrombolytic therapies are effective in recanalizing the veins and preventing post-thrombotic complications, but there is no consensus on selection criteria. The aim of this study was to investigate a fibrin-specific MRI contrast agent (EP-2104R) for the accurate quantification of thrombus' fibrin content in vivo and for the identification of thrombus suitable for thrombolysis. Approach and Results-Venous thrombosis was induced in the inferior vena cava of 8-to 10-week-old male BALB/C mice and MRI performed 2, 4, 7, 10, 14, and 21 days later. Eighteen mice were scanned at each time point pre and 2 hours post injection of EP-2104R (8.0 μmol/kg) with 12 mice at each time point used to correlate fibrin contrast uptake with thrombus' histological stage and fibrin content. Six mice at each time point were immediately subjected to intravascular thrombolytic therapy (10 mg/kg of tissue-type plasminogen activator). Mice were imaged to assess response to lytic therapy 24 hours after thrombolytic treatment. Two mice at each time point were scanned post injection of 0.2 mmol/kg of Gd-DTPA (gadolinium with diethylenetriaminepentacetate, Magnevist, Schering AG, Berlin, Germany) for control purpose. Contrast uptake was correlated positively with the fibrin content of the thrombus measured by Western blotting (R 2 =0.889; P<0.001). Thrombus relaxation rate (R 1 ) post contrast and the change in visualized thrombus size on late gadolinium enhancement inversion recovery MRI pre-EP-2104R and post-EP-2104R injection were the best predictors for successful thrombolysis (area under the curve, 0.989 [95% confidence interval, 0.97-1.00] and 0.994 [95% confidence interval, 0.98-1.00] respectively). Conclusions-MRI with a fibrin-specific contrast agent accurately estimates thrombus fibrin content in vivo and identifies thrombi that are amenable for thrombolysis. (Arterioscler Thromb Vasc Biol. 2014;34:1193-1198.)
D eep vein thrombosis has an annual incidence of ≈1 to 2 per 1000 people. [1] [2] [3] This condition can give rise to the post-thrombotic syndrome, which is a major cause of morbidity, 4, 5 and pulmonary emboli, which may be fatal. [6] [7] [8] The mainstay of current treatment involves anticoagulation to prevent thrombus propagation, 2 but this has little effect on the resolution of a thrombus. 4, 8, 9 A recent randomized control trial has shown that early vein recanalization by thrombolysis reduces post-thrombotic complications in patients with acute proximal deep venous thrombosis. 10 The advent of pharmacomechanical systems to deliver thrombolytics efficiently has also prompted a more aggressive approach to the treatment of this condition. [11] [12] [13] See cover image Thrombolysis is indicated for young thrombi, with older thrombi thought to be less responsive to this treatment. Clinical history and signs at presentation used to determine thrombus age are, however, subjective and unreliable. 12, 14 Thrombus age is also not always an informative determinant of the susceptibility to lysis. Not all fresh thrombi respond to this treatment, which unnecessarily exposes some patients to hemorrhagic complications, whereas some patients with older thrombi seem to respond well. 12, 15, 16 An objective method capable of identifying thrombi susceptible to lysis is therefore needed. [16] [17] [18] Venous thrombi resolve by a process of organization that leads to vein recanalization. [19] [20] [21] During this process, the structure of the thrombus changes with cross-linked fibrin being gradually replaced by collagen. [19] [20] [21] [22] [23] [24] Experimental data suggest that thrombi, rich in fibrin, are more susceptible to thrombolysis than organized, collagen-rich thrombi. 25 As thrombolytic therapies target fibrin within a thrombus, we hypothesized that this molecule represents an imaging target that could better direct lytic therapy. 17, 24, 26 A gadolinium-based fibrin-specific MRI (FSMRI) contrast agent has been used to detect arterial and venous thrombi in both animal models and man. [27] [28] [29] [30] [31] [32] In this study, we sought to investigate whether this fibrin-specific contrast agent allows estimation of the fibrin content of resolving venous thrombi and indicates thrombi that are susceptible fibrinolysis.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

R 1 Relaxivity After Administration of EP-2104R During Thrombus Resolution
In precontrast images the average blood relaxation rate (R 1 ) was 0.68±0.04 s −1 , whereas in post-EP-2104R images the average blood R 1 , 2 hours after contrast agent, was 0.74±0.03 s −1 (P<0.01). Thrombus signal intensity and R 1 were greater after administration of EP-2104R, compared with precontrast images and Gd-DTPA controls ( Figure 1 ). The difference between R 1 of thrombus post and pre contrast (ΔR 1 ) changed during thrombus resolution (P<0.001, 1-way ANOVA) and was greatest at days 7 (ΔR 1 =0.945±0.049 s −1 ; P<0.01; Bonferroni post hoc test compared with day 2) and 10 (ΔR 1 =1.005±0.054 s −1 ; P<0.01; Bonferroni post hoc test compared with day 2; Figure 1A and 1C).
The mean gadolinium concentration in thrombus of mice injected with EP-2104R mirrored the changes in R 1 over time, reaching a maximum gadolinium concentration at days 7 (886±131 μmol/L) and 10 (1116±155 μmol/L; P<0.001; 1-way ANOVA; Figure 1B ). Traces of gadolinium (<10 μmol/L) were detected in thrombus post injection of Gd-DTPA, but did not change during thrombus organization.
Fibrin Content of the Thrombus During Its Resolution
The fibrin content of the thrombus changed during its resolution (Figure 2A and 2B). Fibrin content was greatest at days 7 and 10 after induction. Fibrin content at days 2, 4, 7, 10, 14, and 21 was 1.7±1.1, 5.2±1.4, 9.3±1.9, 9.6±1.4, 6.6±2.4, and 0.9±1.0, respectively (P<0.01; 1-way ANOVA; Figure IIIA in the onlineonly Data Supplement). The fibrin content of the thrombus correlated with thrombus R 1 (R 2 =0.89; P<0.001; Figure 2B ), and the average fibrin content at each time point correlated with the average thrombus gadolinium concentration after the administration of EP-2104R (R 2 =0.95; P<0.001; Figure 2C ).
Change in R 1 Relaxation Rate After Thrombolysis
The inferior vena cava (IVC) blood flow in normal mice, without thrombus, was 0.55±0.05 mL/min. Blood flow in the IVC was not detected 2 days after the induction of thrombosis, and no significant differences were observed in the IVC blood flow at days 2, 4, and 7. After day 7 of thrombus induction, the IVC flow was seen to increase ( Figure IIIB in the online-only Data Supplement). Thrombolysis was most effective between days 7 and 14 ( Figure 3A ; Figure IVA in the online-only Data Supplement), when ΔR 1 was greatest after the administration of EP-2104R ( Figure 3B ). The R 1 relaxation rate before the administration of the contrast agent resulted in a sensitivity of 72% and specificity of 93% to predict successful lysis when R 1 was >1.30 s −1 . The thrombus R 1 relaxation rate after the administration of EP-2104R improved the sensitivity and specificity to predict successful thrombolysis to 94% and 99%, respectively, when R 1 thrombus relaxation rate was >1.59 s −1 post-EP-2104R injection.
Change in Visualized Thrombus After Administration of EP-2104R
Administration of EP-2104R increased the visualized thrombus volume. The difference between visualized thrombus volume pre and post contrast (ΔV t ) is largest between days 7 and 14 on late gadolinium enhancement-FSMRI ( Figure 4C ; Figure Receiver operator curve analysis demonstrated that visualized thrombus volume before the administration of EP-2104R, V t , was not a good predictor of successful lysis (area under the curve=0.748; 95% confidence interval, 0.58-0.92), but after the administration of EP-2104R, the visualized difference in thrombus volume, ΔV t , on late gadolinium enhancement-FSMRI had an area under the curve of 0.972 (95% confidence interval, 0.95-1.00), and an increase in visualized thrombus volume larger than ΔV t =3.5 mm 3 had a sensitivity and specificity to determine successful lysis of 99% and 95%, respectively.
Multivariate regression analysis showed that the change in the visualized thrombus volume pre and post contrast (ΔV t ) and the R 1 relaxation rate postcontrast administration were independent variables that significantly correlated with the change in the IVC blood flow pre and post contrast, β coefficients of 0.087 (P=0.001) and 2.383 (P=0.003), respectively.
Discussion
Tissue-type plasminogen activator, the main lytic agent used in clinical practice, specifically targets fibrin found in thrombus. 23 In vivo quantification of the thrombus fibrin content has, therefore, the potential to direct therapy, both in terms of identifying patients suitable for treatment and in titering the dose of tissuetype plasminogen activator required. We have demonstrated previously that an FSMRI contrast agent, EP-2104R, can visualize acute thrombi in both experimental models and man [27] [28] [29] [30] [31] [32] Nonstandard Abbreviations and Acronyms FSMRI fibrin-specific MRI IVC inferior vena cava but have never quantified previously the changes in contrast agent uptake during thrombus resolution. In this study, we show that uptake of the fibrin-specific contrast agent, EP-2104R, correlates with the fibrin content of a murine thrombus during its resolution and that thrombi with high EP-2104R uptake are more susceptible to lysis by tissue-type plasminogen activator. The change in R 1 relaxation rate and gadolinium content of murine thrombi after administration of EP-2104R was greatest between days 7 and 10 after thrombus induction. Although conventional wisdom suggests that fibrin content is greatest in the early thrombus, in this and our previous studies, we have shown that the fibrin content of thrombus in our model varies over time, with the highest content found at 7 to 10 days. 33 Here, we also showed that the changes in fibrin content of the thrombus correlate well with the spatial and temporal uptake of EP-2104R. These data suggest, therefore, that quantification of EP-2104R uptake could be used as an in vivo measure of thrombus fibrin content.
Venous thrombus resolution in our murine model of thrombosis naturally occurs during a period of 4 weeks in a process reminiscent of wound healing. [20] [21] [22] Accumulation of inflammatory cells and their mediators orchestrates resolution through processes involving fibrinolysis, proteolysis, and neovascularization. 23 In the early thrombus, red blood cells are trapped within strands of fibrin and form the main body of thrombus. As the thrombus resolves, thicker mature fibrin strands predominate and are subsequently replaced by other extracellular matrix proteins, including collagen. 20 As this process progresses, the thrombus gradually becomes incorporated into the vein wall. Thrombus resolution is therefore a dynamic process during which its structure changes over time. We have demonstrated previously that iron-processing mechanisms after the lysis of trapped red blood cells in thrombus determine its longitudinal (T 1 ) relaxation time and that quantification of the relaxation rate (R 1 ) can be used as a surrogate measure of thrombus fibrin content. 33 Direct thrombus R 1 estimation can therefore be used to identify thrombi that are suitable for lysis. However, the data in this study show that by specific targeting of fibrin using the novel contrast agent, EP-2104R, it is possible to significantly improve the sensitivity and specificity of this selection. R 1 rate without contrast agent cannot be used to determine the age of a thrombus. Short thrombus R 1 rates indicate early or mature thrombus, which limits its clinical use if used alone. In addition, despite the development of fast T 1 -mapping protocols, long scan times are still required to accurately quantify thrombus R 1 in vivo, whereas postprocessing software needs careful analysis. Faster late gadolinium enhancement sequences are readily available on commercial MRI scanners and do not require sophisticated postprocessing tools for analysis as needed for R 1 maps. In this study, we used late gadolinium enhancement sequences with our fibrin-specific contrast agent and showed that an increase in the volume of visualized thrombus after the administration of EP-2104R was associated with thrombi that were most amenable to lysis. Although this combination has improved significantly the speed of analysis, 1 limitation is that a pre-and postcontrast agent scan is required.
Conclusions
These data show that the uptake of an FSMRI contrast agent, EP-2104R, changes during the resolution of an experimental venous thrombus. These changes strongly correlate with the fibrin content of the thrombus and uptake of the contrast agent can be used to identify thrombi that are susceptible to fibrinolysis. Although this study was conducted in an experimental model of thrombosis, it was performed using a clinical 3-Tesla field strength MRI scanner. Given that we used sequences that are readily available on commercial MRI scanners, and the safety of this contrast agent is already proven in man, 34 EP-2104R should now be tested in the clinical setting. Deep venous thrombosis is a major health problem. Our results show that the quantification of the fibrin-specific MRI contrast agent, EP-2104R, uptake changes during the resolution of an experimental venous thrombus. These changes strongly correlate with the fibrin content of the thrombus and uptake of the contrast agent can be used to identify thrombi that are susceptible to fibrinolysis. This approach has great potential to increasing the effectiveness of current venous thrombolytic therapy and decreasing the incidence of acute and chronic complications.
Significance
